Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTS-01
- Development stage
- Unknown
- Lead developer
- Mitos Pharmaceuticals
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
MTS-01 is a topical gel formulation containing a cell-permeable, hydrophilic piperidine nitroxide compound with potential radioprotective and antioxidant activity. The active ingredient is Tempol, a stable free radical that acts as an antioxidant and free radical scavenger. By reducing reactive oxygen species (ROS), MTS-01 may protect normal tissues from radiation-induced toxicity such as dermatitis during radiotherapy. It has been investigated for use in preventing or reducing skin toxicities associated with chemoradiation in cancer patients, particularly those undergoing treatment for anal carcinoma and for the prevention of alopecia induced by whole brain radiotherapy[1][4][5][6][8][9].
- Other names
- Tempol (as the active ingredient)topical piperidine nitroxide MTS-01
Beyond the preview
Go deeper on MTS-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTS-01.